Alcaraz Sanabria, AnaCabañas Morafraile, EstherFernández Hinojal, GonzaloVelasco Díez, GuillermoPérez Segura, PedroPandiella, AtanasioGyörffy, BalázsOcaña, Alberto2023-06-222023-06-222022-021664-322410.3389/fimmu.2021.786069https://hdl.handle.net/20.500.14352/71804Targeting K-RAS-mutant non-small cell lung cancer (NSCLC) with novel inhibitors has shown promising results with the recent approval of sotorasib in this indication. However, progression to this agent is expected, as it has previously been observed with other inhibitors. Recently, new immune therapeutics, including vectorized compounds with antibodies or modulators of the host immune response, have demonstrated clinical activity. By interrogating massive datasets, including TCGA, we identified genes that code for surface membrane proteins that are selectively expressed in K-RAS mutated NSCLC and that could be used to vectorize novel therapies. Two genes, CLDN10 and TMPRSS6, were selected for their clear differentiation. In addition, we discovered immunologic correlates of outcome that were clearly de-regulated in this particular tumor type and we matched them with immune cell populations. In conclusion, our article describes membrane proteins and immunologic correlates that could be used to better select and optimize current therapies.engAtribución 3.0 Españajournal articlehttps://doi.org/10.3389/fimmu.2021.786069https://www.frontiersin.org/articles/10.3389/fimmu.2021.786069/fullopen access616.24-006.04577.112575:61K-RASLung adenocarcinomaSurfaceomeGenomic signatureCLDN10 and TMPRSS6Genética médicaOncologíaBioquímica (Biología)2410.07 Genética Humana3201.01 Oncología2302 Bioquímica